Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26


Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.

Torphy TJ, Allen J, Cantin AM, Konstan MW, Accurso FJ, Joseloff E, Ratjen FA, Chmiel JF; Antiinflammatory Therapy Working Group.

Ann Am Thorac Soc. 2015 Sep;12(9):1398-406. doi: 10.1513/AnnalsATS.201506-361OT. Review.


Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators.

Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2.


Treatment of lung infection in patients with cystic fibrosis: current and future strategies.

Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group.

J Cyst Fibros. 2012 Dec;11(6):461-79. doi: 10.1016/j.jcf.2012.10.004. Epub 2012 Nov 6. Review.


Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators.

Pediatr Pulmonol. 2012 Feb;47(2):125-34. doi: 10.1002/ppul.21525. Epub 2011 Aug 9.


Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B; CFRD Guidelines Committee.

Diabetes Care. 2010 Dec;33(12):2697-708. doi: 10.2337/dc10-1768. No abstract available.


Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B; CFRD Consensus Conference Committee.

Diabetes Care. 2010 Dec;33(12):2677-83. doi: 10.2337/dc10-1279. Review. No abstract available.


Improving the care of infants identified through Cystic Fibrosis newborn screening.

Marshall BC, Campbell PW 3rd.

J Pediatr. 2009 Dec;155(6 Suppl):S71-2. doi: 10.1016/j.jpeds.2009.09.004. No abstract available.


A pipeline of therapies for cystic fibrosis.

Ashlock MA, Beall RJ, Hamblett NM, Konstan MW, Penland CM, Ramsey BW, Van Dalfsen JM, Wetmore DR, Campbell PW 3rd.

Semin Respir Crit Care Med. 2009 Oct;30(5):611-26. doi: 10.1055/s-0029-1238919. Epub 2009 Sep 16.


Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group.

Contemp Clin Trials. 2009 May;30(3):256-68. doi: 10.1016/j.cct.2009.01.003. Epub 2009 Jan 15.


Cystic fibrosis foundation: achieving the mission.

Marshall BC, Penland CM, Hazle L, Ashlock M, Wetmore D, Campbell PW 3rd, Beall RJ.

Respir Care. 2009 Jun;54(6):788-95; discussion 795. Review.


Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd; Cystic Fibrosis Foundation.

J Pediatr. 2008 Aug;153(2):S4-S14. doi: 10.1016/j.jpeds.2008.05.005.


Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.

Comeau AM, Accurso FJ, White TB, Campbell PW 3rd, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O'Sullivan BP; Cystic Fibrosis Foundation.

Pediatrics. 2007 Feb;119(2):e495-518.


Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes.

Campbell PW 3rd, White TB.

J Pediatr. 2005 Sep;147(3 Suppl):S2-5. Review. No abstract available.


Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group.

JAMA. 2003 Oct 1;290(13):1749-56.


Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study.

Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB.

J Natl Cancer Inst. 2003 Mar 5;95(5):381-7.


Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis.

LiPuma JJ, Spilker T, Gill LH, Campbell PW 3rd, Liu L, Mahenthiralingam E.

Am J Respir Crit Care Med. 2001 Jul 1;164(1):92-6.


Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report.

Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, Brunzell C, Campbell PW 3rd, Chesrown SE, Duchow C, Fink RJ, Fitzsimmons SC, Hamilton N, Hirsch I, Howenstine MS, Klein DJ, Madhun Z, Pencharz PB, Quittner AL, Robbins MK, Schindler T, Schissel K, Schwarzenberg SJ, Stallings VA, Zipf WB, et al.

Diabetes Res Clin Pract. 1999 Aug;45(1):61-73. Review. No abstract available.


Use of aerosolized antibiotics in patients with cystic fibrosis.

Campbell PW 3rd, Saiman L.

Chest. 1999 Sep;116(3):775-88. Review. No abstract available.


Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis.

Whitby PW, Dick HL, Campbell PW 3rd, Tullis DE, Matlow A, Stull TL.

J Clin Microbiol. 1998 Jun;36(6):1642-5.


Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening.

Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW 3rd, Phillips JA 3rd.

Am J Hum Genet. 1996 Mar;58(3):617-27.

Supplemental Content

Loading ...
Support Center